title: Fenoldopam infusion associated with preserving renal function after aortic cross-clamping for aneurysm repair.
abstract: BACKGROUND
  Cross-clamping of the descending aorta during operative repairs causes sudden, significant reductions in renal function that may persist well beyond arterial clamp release. Commonly used agents, such as dopamine and mannitol, have not consistently affected renal outcome in these high-risk patients. Fenoldopam mesylate is a novel, highly selective dopamine type-1 agonist that preferentially dilates the renal and splanchnic vasculature, but has not been investigated in patients undergoing prolonged aortic clamping for whom adverse renal outcomes should be more likely.
  
  
  RESULTS
  Twenty-two adult patients without significant pre-existing renal dysfunction and presenting for elective repairs of abdominal aortic aneurysms were studied. Fenoldopain mesylate was infused after obtaining baseline values ranging from 0.1 to 1.0 microg/kg/min for the first 24 hours postoperatively to maintain mean arterial pressure +/-25% baseline. Serial renal function indices, including creatinine clearance and electrolyte fractional excretions, were measured at baseline, at aortic clamping and unclamping, and post-clamp release, and were estimated through hospital discharge. Creatinine clearance fell during abdominal exploration and clamping, reaching a nadir with clamp removal. Partial recovery occurred by 2 hours after clamp removal, and returned to baseline values by postoperative day 1 and thereafter. Fractional excretions rose rapidly throughout the operative phase. Total fenoldopam dose was directly related to the baseline creatinine clearance; after clamp removal, creatinine clearance was directly related to the mean arterial pressure at the lowest dose of fenoldopam, and inversely related to the mean arterial pressure at clamp release.
  
  
  CONCLUSIONS
  In elderly patients with severe vascular disease undergoing aneurysmal repairs, the use of a fenoldopam infusion in this open-label, uncontrolled trial was associated with a relatively rapid return of renal function to baseline values, despite profound decreases during aortic cross-clamping. Further studies will be necessary to investigate how fenoldopam infusions compare with traditional therapies.
authors.affiliation: Department of Anesthesiology, University of Maryland School of Medicine, Baltimore 21201-1595, USA.
authors.forename: T B
authors.initials: TB
authors.lastname: Gilbert
authors.forename: J U
authors.initials: JU
authors.lastname: Hasnain
authors.forename: W R
authors.initials: WR
authors.lastname: Flinn
authors.forename: M P
authors.initials: MP
authors.lastname: Lilly
authors.forename: M E
authors.initials: ME
authors.lastname: Benjamin
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001011:Aorta / Q000601:surgery*; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery*; D013504:Cardiovascular Surgical Procedures / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D018818:Fenoldopam / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000098:blood supply* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control*; D013525:Surgical Instruments; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D018818:Fenoldopam